newwin
Luciann Nguyen
Settings
← Accounts
biotech

Fondazione IRCCS Policlinico San Matteo di Pavia

32
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Fondazione IRCCS Policlinico San Matteo di Pavia

New trial — First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)

New trialNCT07190677
32/100
Opportunity
Commercial fit0/25
Clinical timing13/20
Biomarker need0/20
Relationship2/10
Signal strength9/10
Account value7/10
Urgency1/5

New unknown trial NCT07190677 posted by Fondazione IRCCS Policlinico San Matteo di Pavia: "First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)". New trial on a unknown recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 349 days ago.

ConfidenceHigh · 80%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT07190677
First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)
unknown
—